A Clinical Trial Evaluating the Safety and Efficacy of a New Light Combination Therapy Addressing Intermediate AMD

Inclusion Criteria: * Male and female patients ≥ 50 years of age * Intermediate AMD, Grade AREDS 3 * Both eyes eligible for the study Patients willing to enrol in a clinical study must sign a written informed consent form, cooperate with protocols, and comply with follow-up. * Dietary supplements and life-style habits must remain unchanged, as far as possible, for the duration of investigation participation. Exclusion Criteria: * Myopia \> 8D * Maximum pupillary aperture ᴓ4mm with medical dilation * Anticipation of ocular surgery during the study * Clinically significative cataract * Ocular surgery 6 months or less before study entry * No previous retinal treatment, neither anti-VEGF (Anti-Vascular Endothelial Growth Factor ) therapy nor laser photocoagulation * Diabetic retinopathy * Any other maculopathy and conditions as e.g. retinitis pigmentosa, DME (diabetic macular oedema), retinal lesions, retinal vessel occlusions etc * Another obfuscating ocular disease including amblyopia, uncontrolled IOP (intraocular pressure), uncontrolled glaucoma or glaucomatous visual field loss, media opacity such as visually significant cataract, epiretinal membrane, vitreomacular traction, etc * Concomitant systemic diseases and factors affecting the study, as per investigator's discretion * Pregnant and lactating woman * Concomitant participation in another interventional clinical study * When it is expected that the patient will not be able to complete the trial due to mental health, age, or other personal issues. * Photosensitivity